Group items matching

in title, tags, annotations or url

TTSA supports hypothesis-driven translational studies. These studies should be associated with an ongoing or completed clinical trial and/or annotated biorepositories and focused on research for the next-phase clinical trial or future clinical application. The TTSA is intended to support advanced translational studies that have the potential for near-term outcomes that are based on results from clinical investigations. While funding for clinical trials is allowed, the TTSA is intended to fund correlative clinical research studies and not only a clinical trial. Research projects funded by the TTSA should address critical knowledge gaps in clinical outcomes, validate key research results, expand upon potentially transformative results, or investigate novel findings based on results from clinical research.

The FY17 HRRP TRA mechanism is being offered in this first year of the program to support preclinical translational research that will accelerate the movement of promising initiatives relevant to hearing restoration into clinical applications. The ultimate goal of translational research is to move an observation forward into clinical application and accelerate the clinical introduction of healthcare products, technologies, or practice guidelines. Observations that drive a research idea may be derived from a laboratory discovery, population-based studies, or a clinician's first-hand knowledge of patients and anecdotal data. However, Principal Investigators (PIs) should not view translational research as a one-way continuum from bench to bedside. The research plan should involve a reciprocal flow of ideas and information between basic and clinical science.

Grants are targeted primarily to new or junior investigators within seven years of attaining a terminal degree (e.g., PhD, EdD), and are expected to provide seed-money support after which further funding will be sought from other sources.

The PhRMA Foundation is accepting applications for its Health Outcomes program. Health outcomes research spans a broad spectrum of issues related to healthcare delivery, from studies evaluating the effectiveness of a pharmaceutical intervention to the impact of reimbursement policies on outcomes of care. It also ranges from the development of tools to perform patient-based assessments to analyses of the ways in which results of outcomes research are disseminated to providers or consumers to encourage behavior change.

The Anesthesia Patient Safety Foundation (APSF) and The Foundation for Anesthesia Education and Research (FAER) offer the joint APSF/FAER Mentored Research Training Grant (MRTG) to develop the next generation of perioperative patient safety scientists.

Encourages new investigators by providing seed and start-up funding for promising research projects that address issues related to the treatment of arthritis with an emphasis on arthroplasty. Clinical relevance must be clearly noted in the abstract and specific aims, and be obvious from the title and the study design. All proposed projects should generate results that have a practical application. It is expected that upon completion of the proposed project, the principal investigator will be well poised to pursue NIH/DOD or the equivalent large-scale funding to continue to advance the area of research.

Applications must articulate how results will lead to a clinical impact for Veterans with GWI even if a clinical impact is not an immediate outcome. All applications must focus on features of GWI and Veterans of the 1990-1991 Gulf War affected by GWI. It is the responsibility of the Principal Investigator (PI) to clearly and explicitly articulate the project's potential impact on GWI. The types of activities supported include, but are not limited to, expansion of limited data on candidate markers, mechanistic targets; therapeutics and interventions; validation and advanced research on druggable mechanistic targets, identification and development of leading compounds, and collection of preclinical data for repurposing an existing approved drug or for new Investigational New Drug (IND) application submissions to the U.S. Food and Drug Administration (FDA). Applicants proposing to test FDA-approved drugs in animal models for efficacy must explain why preclinical testing is required prior to clinical pilot trials in humans

The intent of the FY19 PRARP InCASA is to support innovative research that improves the quality of life and care for individuals living with the common symptoms of TBI and/or AD/ADRD and/or their families and care providers, as related to the PRARP's mission (see Section II.A, Program Description). The proposed work should innovatively challenge existing research paradigms or exhibit high levels of creativity within the contexts of the PRARP's mission and vision. This can include innovations and research for symptom reduction (e.g., cognitive, behavioral, function, mood), resiliency factors, increasing or maintaining independence, and support for families and care providers. The research innovations for the FY19 PRARP InCASA are expected to benefit the military, Veteran, and civilian communities. FY19 PRARP InCASA applications should be Innovation- and Impact-based.

The research projects will focus on Health Promotion: * Strategies for habit change: prevention of obesity and promotion of physical activity. * Patient education. * Physical injury assessment. * Health management: clinical quality and safety. In this call, special attention will be given to the projects which, while taking into account the previous topic lines, incorporate aspects related to COVID-19 such as: reducing infections, self-care and the culture of self-protection, relationship between previous health status (lifestyle) and morbimortality, COVID-19 and mental health, etc.

LEO Foundation 'Open competition grants' are given to support the best dermatology research projects worldwide. Thus, we welcome applications from research projects that: - Improve the understanding of the underlying medicinal, biological, chemical, or pharmacological mechanisms of dermatological diseases and their symptoms - Address clinical issues among people who are at risk of developing, or have developed, a skin disease, including how it impacts their quality of life and the societal costs involved